High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia

@article{Voskaridou2010HighCL,
  title={High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia},
  author={Ersi Voskaridou and Dimitrios Christoulas and Athanasios Papatheodorou and Cornelia Bratengeier and Eleni Plata and Despoina Kaliontzi and Wolfgang Woloszczuk and Evangelos Terpos},
  journal={Blood},
  year={2010},
  volume={116},
  pages={1010-1010}
}
Abstract 1010 Osteoporosis represents an important cause of morbidity in adult patients with thalassemia. Osteoclast activity is elevated in thalassemia-induced osteoporosis, and thus bisphosphonates have been used for its management. Moreover, osteoblasts are also deregulated in thalassemia patients but there is very limited data for the underlying mechanisms of this deregulation. Osteocyte seems to be a key cell for the control of bone remodeling. Sclerostin is a secreted inhibitor of the… 

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy

It is suggested that patients with active myeloma have elevated circulating sclerostin, which correlated with advanced disease features including severe bone disease, and is indicated as a possible target for the development of novel therapies to enhance osteoblast function in myelomas.

Treatment for osteoporosis in people with ß-thalassaemia.

The evidence on the efficacy and safety of treatment for osteoporosis in people with beta-thalassaemia is reviewed, with significant increases in favour of the bisphosphonate group for bone mineral density at the lumbar spine and hip at both six and 12 months.

Physiopathology of Bone Modifications in β-Thalassemia

The most recent findings on the physiopathology of bone abnormalities in βTM are reviewed and clinical presentation and radiological features of βTM-related bone changes are discussed.

β-Thalassemia: New Therapeutic Modalities, Genetics, Complications, and Quality of Life

This special issue of Anemia presents some of the most cutting-edge research outcomes pertaining to the latest complications and the novel treatment strategies in iron-chelation therapy, as well as comparing the quality of life in patients with β-thalassemia major and myelodysplastic syndrome with iron-overload treated either with deferasirox or deferoxamine injections.

Calcification Propensity of Serum is Independent of Excretory Renal Function

Findings indicate that T50 values depend mainly on the concentration of promoters and inhibitors of calcification in serum, but not excretory kidney function.

Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort.

Anti-TNF therapy is protective against bone loss and baseline use of NSAIDs has a protective effect on hip bone loss among patients with symptoms suggestive of early axial SpA.